Detalhe da pesquisa
1.
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G.
Oncologist
; 2024 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38873934
2.
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial.
Oncologist
; 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38815151
3.
Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
Blood
; 137(26): 3595-3603, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33684925
4.
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.
Blood Adv
; 8(5): 1116-1127, 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38163318
5.
Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1.
J Clin Oncol
; 41(11): 2043-2053, 2023 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36534942
6.
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
J Natl Cancer Inst
; 115(11): 1355-1363, 2023 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37228094
7.
Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321).
J Clin Oncol
; 40(33): 3839-3847, 2022 11 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35820112
8.
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.
J Clin Oncol
; 40(20): 2235-2245, 2022 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35363510
9.
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.
J Clin Oncol
; 40(20): 2224-2234, 2022 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35353553